1472 related articles for article (PubMed ID: 25986029)
1. Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values.
Pfaller MA; Rhomberg PR; Messer SA; Jones RN; Castanheira M
Diagn Microbiol Infect Dis; 2015 Aug; 82(4):303-13. PubMed ID: 25986029
[TBL] [Abstract][Full Text] [Related]
2. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance.
Pfaller MA; Messer SA; Woosley LN; Jones RN; Castanheira M
J Clin Microbiol; 2013 Aug; 51(8):2571-81. PubMed ID: 23720791
[TBL] [Abstract][Full Text] [Related]
3. Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections.
Castanheira M; Messer SA; Jones RN; Farrell DJ; Pfaller MA
Int J Antimicrob Agents; 2014 Oct; 44(4):320-6. PubMed ID: 25129315
[TBL] [Abstract][Full Text] [Related]
4. In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds.
Pfaller MA; Messer SA; Rhomberg PR; Jones RN; Castanheira M
J Clin Microbiol; 2013 Aug; 51(8):2608-16. PubMed ID: 23740727
[TBL] [Abstract][Full Text] [Related]
5. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
6. Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program.
Pfaller MA; Messer SA; Rhomberg PR; Castanheira M
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052853
[TBL] [Abstract][Full Text] [Related]
7.
Pfaller MA; Rhomberg PR; Wiederhold NP; Gibas C; Sanders C; Fan H; Mele J; Kovanda LL; Castanheira M
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30061288
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan.
Yamazaki T; Inagaki Y; Fujii T; Ohwada J; Tsukazaki M; Umeda I; Kobayashi K; Shimma N; Page MG; Arisawa M
Int J Antimicrob Agents; 2010 Oct; 36(4):324-31. PubMed ID: 20674282
[TBL] [Abstract][Full Text] [Related]
9. Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values.
Castanheira M; Messer SA; Rhomberg PR; Dietrich RR; Jones RN; Pfaller MA
Mycopathologia; 2014 Aug; 178(1-2):1-9. PubMed ID: 24952015
[TBL] [Abstract][Full Text] [Related]
10. In vitro combination therapy with isavuconazole against Candida spp.
Katragkou A; McCarthy M; Meletiadis J; Hussain K; Moradi PW; Strauss GE; Myint KL; Zaw MH; Kovanda LL; Petraitiene R; Roilides E; Walsh TJ; Petraitis V
Med Mycol; 2017 Nov; 55(8):859-868. PubMed ID: 28204571
[TBL] [Abstract][Full Text] [Related]
11. In vitro antifungal susceptibilities of isolates of Candida spp. and Aspergillus spp. from China to nine systemically active antifungal agents: data from the SENTRY antifungal surveillance program, 2010 through 2012.
Pfaller MA; Castanheira M; Messer SA; Jones RN
Mycoses; 2015 Apr; 58(4):209-14. PubMed ID: 25727853
[TBL] [Abstract][Full Text] [Related]
12. EUCAST Susceptibility Testing of Isavuconazole: MIC Data for Contemporary Clinical Mold and Yeast Isolates.
Jørgensen KM; Astvad KMT; Hare RK; Arendrup MC
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30910898
[TBL] [Abstract][Full Text] [Related]
13. Isavuconazole MIC distribution of 29 yeast species responsible for invasive infections (2015-2017).
Desnos-Ollivier M; Bretagne S; Boullié A; Gautier C; Dromer F; Lortholary O;
Clin Microbiol Infect; 2019 May; 25(5):634.e1-634.e4. PubMed ID: 30771532
[TBL] [Abstract][Full Text] [Related]
14. Antifungal susceptibility profiles of bloodstream yeast isolates by Sensititre YeastOne over nine years at a large Italian teaching hospital.
Posteraro B; Spanu T; Fiori B; De Maio F; De Carolis E; Giaquinto A; Prete V; De Angelis G; Torelli R; D'Inzeo T; Vella A; De Luca A; Tumbarello M; Ricciardi W; Sanguinetti M
Antimicrob Agents Chemother; 2015 Jul; 59(7):3944-55. PubMed ID: 25896705
[TBL] [Abstract][Full Text] [Related]
15. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009).
Pfaller MA; Castanheira M; Messer SA; Moet GJ; Jones RN
Diagn Microbiol Infect Dis; 2011 Jan; 69(1):45-50. PubMed ID: 21146713
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility to echinocandins of Candida spp. strains isolated in Italy assessed by European Committee for Antimicrobial Susceptibility Testing and Clinical Laboratory Standards Institute broth microdilution methods.
Montagna MT; Lovero G; Coretti C; Martinelli D; De Giglio O; Iatta R; Balbino S; Rosato A; Caggiano G
BMC Microbiol; 2015 May; 15():106. PubMed ID: 25990252
[TBL] [Abstract][Full Text] [Related]
17. Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates (SENTRY Program, 2016 to 2018).
Pfaller MA; Carvalhaes C; Messer SA; Rhomberg PR; Castanheira M
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015043
[TBL] [Abstract][Full Text] [Related]
18. Isavuconazole: A new broad-spectrum azole. Part 1: In vitro activity.
Denis J; Ledoux MP; Nivoix Y; Herbrecht R
J Mycol Med; 2018 Mar; 28(1):8-14. PubMed ID: 29534853
[TBL] [Abstract][Full Text] [Related]
19. Antifungal susceptibilities of Candida, Cryptococcus neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: data from the SENTRY antifungal surveillance program (2010-2012).
Pfaller MA; Messer SA; Jones RN; Castanheira M
J Antibiot (Tokyo); 2015 Sep; 68(9):556-61. PubMed ID: 25899126
[TBL] [Abstract][Full Text] [Related]
20. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
Guinea J; Peláez T; Recio S; Torres-Narbona M; Bouza E
Antimicrob Agents Chemother; 2008 Apr; 52(4):1396-400. PubMed ID: 18212101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
